Clear Search sequence regions
Bookmark Forward

QuickView for Etretinate (compound)


PubChem
Name: Etretinate
PubChem Compound ID: 3312
Description: An oral retinoid used in the treatment of keratotic genodermatosis, lichen planus, and psoriasis. Beneficial effects have also been claimed in the prophylaxis of epithelial neoplasia. The compound may be teratogenic.
Molecular formula: C23H30O3
Molecular weight: 354.483 g/mol
DrugBank
Identification
Name: Etretinate
Name (isomeric): DB00926
Drug Type: small molecule
Description: An oral retinoid used in the treatment of keratotic genodermatosis, lichen planus, and psoriasis. Beneficial effects have also been claimed in the prophylaxis of epithelial neoplasia. The compound may be teratogenic.
Brand: Tegison, Tigason
Category: Keratolytic Agents
CAS number: 54350-48-0
Pharmacology
Indication: For the treatment of severe psoriasis in adults.
Pharmacology:
The active metabolite responsible for etretinate's effects, acitretin, is a retinoid. Retinoids have a structure similar to vitamin A and are involved in the normal growth of skin cells. Acitretin works by inhibiting the excessive cell growth and keratinisation (process by which skin cells become thickened due to the deposition of a protein within ...
show more »
Mechanism of Action: The mechanism of action of the active metabolite, acitretin, is unknown, however it is believed to work by targeting specific receptors (retinoid receptors) in the skin which help normalize the growth cycle of skin cells.
Absorption: Absorbed in the small intestine. Studies in normal volunteers indicate that the absorption of etretinate is greater in patients consuming whole milk or a high-fat diet than in patients in a fasting state.
Protein binding: More than 99% bound to plasma proteins, predominantly lipoproteins, whereas its active metabolite, acetretin (etretin), is predominantly bound to albumin.
Biotransformation: Extensively metabolized, with significant first-pass metabolism to the pharmacologically active acid form. Subsequent metabolism results in the inactive 13-cis acid form, chain-shortened breakdown products, and conjugates that are ultimately excreted.
Half Life: In one study, the apparent terminal half-life of etretinate after 6 months of therapy was approximately 120 days. In another study of 47 patients who had undergone chronic therapy with etretinate, 5 patients had detectable serum drug concentrations (0.5 to 12 ng/mL) 2.1 to 2.9 years after therapy was completed.
Toxicity: Symptoms of overdose include headache and vertigo.
Affected organisms: Humans and other mammals
Interactions
Food interaction:
Avoid alcohol completely up to 2 months after discontinuation.
Increases absorption, take with food.
Drug interaction:
TetracyclineIncreased risk of intracranial hypertension
MethotrexateAcitretin/etretinate increases the effect and toxicity of methotrexate
MinocyclineIncreased risk of intracranial hypertension
MethacyclineIncreased risk of intracranial hypertension
RolitetracyclineIncreased risk of intracranial hypertension
show more »

Targets


Enzymes


Carriers